Premium
Defining the ends of Parkin exon 4 deletions in two different families with Parkinson's disease
Author(s) -
Clarimon Jordi,
Johnson Janel,
Dogu Okan,
Horta Wagner,
Khan Naheed,
Lees Andrew J.,
Hardy John,
Singleton Andrew
Publication year - 2005
Publication title -
american journal of medical genetics part b: neuropsychiatric genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.393
H-Index - 126
eISSN - 1552-485X
pISSN - 1552-4841
DOI - 10.1002/ajmg.b.30119
Subject(s) - genetics , parkin , exon , biology , point mutation , mutation , parkinsonism , breakpoint , disease , parkinson's disease , gene , chromosomal translocation , medicine
Abstract Autosomal recessive juvenile parkinsonism (AR‐JP, PARK2 ) is characterized by an early onset parkinsonism, often presenting with dystonia as an early feature. Mutations in Parkin are a relatively common cause of AR‐JP and are estimated to be present in ∼30% of familial young onset Parkinson disease (PD) [Abbas et al. (1999); Hum Mol Genet 8:567–574]. These mutations include exon rearrangements (deletions and duplications), point mutations, and small deletions. Similar genomic mutations have been described in unrelated patients, thereby indicating independent mutational events or ancient founder effects. We have identified homozygous deletion mutations of exon 4 in Parkin in two unrelated families, one from Brazil and the other from Turkey [Dogu et al. (2004); Mov Dis 9:812–816; Khan et al., Mov Dis, in press]. We have performed molecular analysis of the deletion breakpoints and this data indicates these mutations originated independently. We present here data demonstrating that the mutation responsible for disease in the Brazilian kindred consists of two separate deletions (1,069 and 1,750 bp) surrounding and including exon 4. The deletion removing parkin exon 4 identified in the Turkish family extended 156,203 bp. In addition to demonstrating that disease in these families is not caused by a single founder mutation, these data show that there is no common fragile site between these mutational events. © 2004 Wiley‐Liss, Inc.